Anteris Technologies Ltd. announced a summation of the Company's presentation at the New York Valves annual Conference held at the Jacob K. Javits Convention Center in New York City. Dr. Anita Asgar, Institut de Cardiologie de Montreal, presented a series of cases from five high-risk patients who underwent valve-in-valve (ViV) procedures using DurAVR?? THV.

The patients were treated under Health Canada's special access program (SAP) which allows health care professionals to access unlicensed medical devices, such as DurAVR??, for emergency use when conventional therapies have failed, are unavailable, or are unsuitable to treat a patient. While TAVR procedures have revolutionized heart valve replacement, up to 30% of patients may eventually require a second valve due to deterioration of the first implant1. Transcatheter ViV replacement is performed by implanting a transcatheter heart valve within a failing bioprosthetic aortic valve.

The transcatheter ViV operation is a less invasive procedure compared with reoperative surgical aortic valve replacement however this repeat procedure presents unique challenges for both doctors and patients. Restoring Valve Hemodynamics with DurAVR?? ViV implantation with DurAVR??THV successfully reduced aortic valve gradients to a level similar to the initial post-surgical valve gradient.

Average aortic valve gradients across the series of 5 cases: Post-surgical valve replacement gradient (8-13 years prior) = 13.82 mmHg; Mean gradient prior to ViV = 58.60 mmHg; 30 day core lab echo data post DurAVR?? Vi V = 13.76 mmHg. No major complications were reported.